Welcome to our dedicated page for MESOBLAST SEC filings (Ticker: MESO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MESOBLAST's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MESOBLAST's regulatory disclosures and financial reporting.
Mesoblast Ltd director George Gregory filed an initial Form 3 detailing his derivative holdings in MESO. The filing lists indirect warrants over 6,830,602 ordinary shares at an exercise price of $2.86 expiring in 2028, plus direct warrants over 200,000 ADS at $9.06 and 1,600,000 ordinary shares or ADS at $2.50 expiring between 2028 and 2029.
He also holds three option tranches over 66,667, 66,667 and 66,666 ordinary shares at $1.72 per share, which become exercisable between 2026 and 2028 and expire in 2032. The Form 3 reports these existing positions and does not show new purchases or sales.
Mesoblast Limited reported that Dr. Teresa Montagut, MD, PhD, has been appointed to the newly created role of Head of Clinical Development and Medical Affairs, reporting to Chief Medical Officer Dr. Eric Rose. She will lead medical affairs, clinical collaborations, investigator-initiated trials, and engagement with healthcare professionals.
Dr. Montagut previously held senior medical and development roles at Regeneron, Novartis, Genentech, and Atara Biotherapeutics, and trained at leading U.S. institutions including Memorial Sloan Kettering Cancer Center. The company highlights her importance in advancing Ryoncil®, its FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease, and in expanding Mesoblast’s broader inflammatory disease and cell therapy pipeline.
Mesoblast Limited reported a sharp jump in activity for the half-year ended December 31, 2025, as the U.S. launch of Ryoncil drove total revenue to US$51.3 million, up from US$3.2 million a year earlier. Net loss narrowed to US$40.2 million from US$47.9 million, helped by high Ryoncil gross margins and tight cost control.
Ryoncil generated US$48.7 million of revenue and a gross profit of US$44.2 million, funding increased R&D spending of US$46.2 million on late-stage programs in chronic low back pain and heart failure. The company ended the period with cash of US$129.975 million, access to a US$125.0 million five-year credit line, and guided full-year fiscal 2026 Ryoncil net revenue to US$110–120 million.
Mesoblast Limited is informing investors that it will host a webcast to discuss operational highlights and financial results for the half year ended December 31, 2025. The webcast is scheduled for 5:00 p.m. EST on Thursday, February 26, and 9:00 a.m. AEDT on Friday, February 27, 2026, and can be accessed online at the provided webcast link.
Mesoblast describes itself as a world leader in developing allogeneic, off-the-shelf cellular medicines for severe inflammatory conditions. Its therapy Ryoncil® (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients is stated to be the first FDA-approved mesenchymal stromal cell therapy, and the company is advancing additional indications and partnerships globally.
Mesoblast Limited reported strong commercial and funding progress for the quarter ended December 31, 2025. Ryoncil® gross sales reached US$35 million, up 60% from the prior quarter, with net revenues of US$30 million, reflecting growing uptake in pediatric steroid‑refractory acute graft‑versus‑host disease.
The company entered a new US$125 million non‑dilutive credit line at a fixed 8.00% interest rate and drew US$75 million, which helped refinance higher‑cost debt. Mesoblast held US$130 million in cash at December 31, 2025, after a quarterly net operating cash outflow of US$16 million, and estimates about 11.6 quarters of total funding based on current burn and available facilities.
Operationally, early ‘real‑world’ data from the first 25 Ryoncil® patients post‑launch showed 21 alive after completing the initial 28‑day regimen. A pivotal adult SR‑aGvHD trial is expected to begin site enrollment this quarter. The FDA provided positive feedback on a potential BLA for rexlemestrocel‑L in chronic low back pain, and a confirmatory Phase 3 trial targeting 300 patients is actively recruiting across 40 U.S. sites.
Mesoblast Limited reports early real-world experience and commercial rollout of its FDA-approved cell therapy Ryoncil for children with steroid‑refractory acute graft‑versus‑host disease. Among the first 25 patients treated after launch, 21 were alive after completing the 28‑day course, an 84% survival rate. Access efforts include a MyMesoblast patient hub, onboarding of 45 U.S. transplant centers toward a target of 64 centers covering 94% of transplants, and payer coverage reaching more than 260 million U.S. lives. Mesoblast plans a pivotal adult SR‑aGvHD trial with the NIH‑funded BMT‑CTN expected to begin site enrollment this quarter and is also developing its stromal cell platform for additional inflammatory and cardiovascular indications.
Mesoblast Limited submitted a foreign issuer report describing an action first disclosed on the Australian Securities Exchange. On December 17, 2025, the company lodged an Appendix 3G with the ASX, which relates to a new issue announcement and the issue, conversion or payment up of unquoted equity securities. This Appendix 3G document is attached to the report as an exhibit and is incorporated by reference for further details.
Mesoblast Limited furnished a Form 6-K to provide investors with Australian Securities Exchange materials. The filing attaches two ASX documents dated October 28, 2025: an Appendix 3Y change of director’s interest notice and an Appendix 3G notification of issue, conversion or payment up of unquoted equity securities, incorporated by reference as Exhibits 99.1 and 99.2.
This update is administrative, making the ASX disclosures available to U.S. investors under the Exchange Act.